Abcuro
Garry Weems has a strong background in clinical science, with experience in various leadership roles at companies such as Abcuro, Inc, Avalo Therapeutics, Lycera, Arbor Pharmaceuticals, Allos Therapeutics, and MGI Pharma. Garry holds a PharmD from the University of Minnesota and completed their education at Bethel University.
This person is not in any offices
Abcuro
2 followers
Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies.